Blog

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will present at the Maxim Growth Summit, being held October 22-23, 2025, in New York City.

This summit brings together industry leaders, innovators, thought leaders, opinion makers and premier institutions to explore the latest trends and advancements across several industries.

Event Details
Date: October 22-23, 2025
Location: Hard Rock Hotel, New York City

Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, will deliver an overview of the Company in a Fireside Chat hosted by Maxim analyst, Dr. Jason McCarthy and provide an update on the clinical development program of its two therapeutic assets:

1. Skinject, a novel immuno-oncology precision product, focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) of the skin, representing ~$2 billion in potential market opportunity.

2. Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate, collectively representing ~$6 billion in potential market opportunity.

A webcast of the Fireside Chat will be available on-demand to registered conference attendees. Dr. Bokhari will also meet with institutional investors registered for the conference in one-on-one format.

The conference will also feature roundtable discussions with CEOs from small and mid-cap companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, and more.

For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit.

Medicus is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. SKNJCT-003 is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable Doxorubicin-containing microneedle arrays (D-MNA). In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed.In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the Company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.

The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

For further information contact:

Carolyn Bonner, President and Acting Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / October 16, 2025 / Every online transaction begins with faith. Buyers believe what they see, sellers rely on reputation, and platforms depend on perception. For two decades, that faith has been the foundation of e-commerce. But faith has limits. Visual verification can only go so far, and counterfeiters have long learned to stay one step ahead of human detection. They have gotten so good, in fact, that even experts are now often fooled.

SMX (NASDAQ:SMX) is changing that probability by putting a much more important product attribute under the microscope: PROOF. The company’s invisible, immutable molecular marker technology introduces a new standard of truth and proof to global commerce, providing a layer of invisible infrastructure that replaces subjective verification with quickly scanned scientific evidence. For platforms that depend on credibility, that shift is not just an improvement; it is a revolution that can be worth millions in cost savings and lost sales.

The Science of Trust at the Source

Here’s what makes it work: SMX does not authenticate after the fact. It starts at the source. SMX embeds molecular markers directly into the materials that make up consumer goods, including polymers, metals, textiles, and liquids. From the moment a product is created, it carries a permanent molecular identity that can be read instantly with a simple scan.

Through global partnerships with organizations such as CETI, Aegis Packaging, and A*STAR in Singapore, this concept is already in motion. Factories, suppliers, and packaging producers are integrating SMX markers into their production lines, giving each product a molecular “birth certificate.” By the time it reaches a resale platform or consumer marketplace, there is no need for human inspection. The proof is already in the product.

That is the essence of SMX’s innovation. It moves authentication from a reactive to a proactive approach. Instead of catching counterfeits after they appear, the company locks in authenticity before the first sale. Every transaction that follows can be verified instantly.

When Proof Replaces Perception

For e-commerce platforms, the implications are enormous. Every listing, sale, and resale can now be verified with precision and speed. Human authentication centers, once the gold standard, can become optional. That is not disruption. It is evolution.

In this model, marketplaces become the checkpoints of truth. They no longer guess or outsource authentication. They scan, confirm, and connect verified data back to the product’s original source. It is a faster, cleaner, and more defensible system that strengthens trust at every point in the value chain.

Luxury brands and manufacturers benefit in the same way. With SMX’s molecular memory built into materials, counterfeiting becomes exponentially harder. A watch, handbag, or collectible with an embedded SMX signature carries an immutable record of authenticity, adding value with every transfer. Proof no longer stops at the first sale. It compounds through every resale.

That is how brand integrity and consumer confidence grow together.

Building a Global Verification Network

Once proof exists at the molecular level, it does not stay confined to luxury goods. It scales across industries. Imagine refurbished electronics verified before resale. Pharmaceutical packaging traced from lab to patient. Industrial materials tracked from production to recycling. Even art and collectibles carry digital passports that automatically record provenance.

Each use case contributes to SMX’s network, a global verification web that connects production, commerce, and recycling through a single, continuous digital memory. This is not an add-on for eCommerce. It is the infrastructure for the next era of supply chain transparency.

Proof as a Platform

The business case is equally compelling. Every scan, verification, and authenticated resale generates value. SMX’s system functions as both a security layer and a data engine, providing analytics that measure authenticity, movement, and lifecycle in real time.

That data holds enormous potential for brands looking to protect equity, for regulators monitoring compliance, for customs agents tracking counterfeits, and for consumers demanding transparency. It transforms authenticity into a measurable, monetizable asset.

Because SMX’s platform integrates directly with the manufacturing layer through partners such as CETI and A*STAR, it scales naturally. From fashion to electronics, automotive to fine art, the same molecular framework can secure every supply chain where proof matters more than promises.

The New Currency of Commerce

Marketplaces may remain the checkpoints, but SMX is redefining the standard against which they verify.

By linking every stage of a product’s life through molecular proof, SMX is offering the world authenticity that is automated, trust is transferable, and proof itself becomes currency.

It’s a win for manufacturers protecting brand equity. It’s a win for platforms, as it reduces fraud and overhead. And it’s a win for consumers who finally get verifiable truth with every purchase. It points to this: The next revolution in eCommerce will not be about faster delivery or smarter algorithms. It will be about proof. And it can be the most significant upgrade in the history of online sales. The best part, it’s available today.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring, and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters)

View the original press release on ACCESS Newswire

SASKATOON, SK / ACCESS Newswire / October 16, 2025 / Creative Compliments™, Saskatchewan’s leading provider of gift baskets and floral designs, has been awarded the 2025 Consumer Choice Award in the Gift Baskets category for Saskatoon. Celebrating 38 years of business, Creative Compliments™ continues to be recognized for its exceptional creativity, quality, and customer service, setting the standard for professional gifting across the province.

Established in 1988, Creative Compliments™ has built a reputation as the province’s most trusted name in custom gifting. Proudly serving all of Saskatchewan and shipping across Canada, the company is known for its distinctive, high-quality designs and commitment to customer satisfaction. Each arrangement is thoughtfully curated to reflect both the occasion and the recipient, ensuring every gift makes a lasting impression.

“Our name says it all – creativity is at the heart of everything we do,” says the Creative Compliments™ team. “We take pride in creating meaningful, memorable gifts that reflect our clients’ sentiments and exceed their expectations every time.”

From corporate clients looking to express appreciation, to individuals celebrating milestones, holidays, and special occasions, Creative Compliments™ delivers tailored designs that are as unique as the people receiving them.

A Legacy of Excellence and Recognition

Now in its 38th year, Creative Compliments™ has become synonymous with quality craftsmanship and reliable service. Over the decades, the company has received numerous honours, including Tourism Saskatchewan’s Service Excellence Award, the Saskatoon Achievement in Business Excellence (SABEX) Award, and recognition as a finalist for the Saskatchewan Achievement in Business Excellence (ABEX) Awards.

In addition, Creative Compliments™ was featured in a Reader’s Digest issue highlighting exceptional customer service – a distinction that speaks to the company’s long-standing reputation for care, professionalism, and integrity.

The 2025 Consumer Choice Award adds to this impressive record, further affirming Creative Compliments™ as a trusted leader in Saskatchewan’s business community.

Creativity, Quality, and Care

At Creative Compliments™, every design begins with a simple philosophy: combine originality with precision. The company’s team of experienced designers and florists crafts each basket and arrangement with attention to detail, aesthetic balance, and purpose. Whether creating gourmet baskets, corporate collections, or floral displays, the team emphasizes three core principles: creative design, timely delivery, and on-budget execution.

These guiding values ensure that every client receives not only a beautiful product but also a seamless and reliable experience.

“We understand that every gift tells a story,” says the team. “Our job is to make sure that story is told beautifully, on time, and with care. That’s what has kept our customers coming back year after year.”

Trusted by Individuals and Businesses Alike

Creative Compliments™ serves a diverse clientele ranging from private customers to corporations, tourism organizations, and event professionals. Its commitment to service excellence and customized solutions has made it a preferred partner for companies seeking professional, branded gifts that leave a lasting impression.

From elegant holiday hampers and appreciation baskets to themed creations for corporate milestones, the team’s creative range ensures that every gift reflects the client’s message, style, and budget. The company’s reach extends well beyond Saskatoon, with delivery across the province and shipping available Canada-wide.

Recognition Backed by Research

The Consumer Choice Award is the only organization in North America that recognizes business excellence based on independent market research. Winners are selected through unbiased surveys that evaluate consumer perceptions, satisfaction, and overall brand reputation.

For Creative Compliments™, receiving this honour reflects the continued trust of clients and the impact of its long-standing commitment to quality and creativity.

“We’re thrilled to receive this award,” says the team. “After nearly four decades in business, we remain as passionate as ever about what we do. This recognition from our customers and community is truly an honour – and it inspires us to keep raising the bar.”

The Art of Thoughtful Gifting

As consumer preferences evolve, Creative Compliments™ remains focused on innovation and personalization. The company continually updates its designs and offerings to reflect modern trends while maintaining the craftsmanship and personal touch that define its brand.

Looking to the future, Creative Compliments™ plans to expand its online capabilities, explore new design collaborations, and continue enhancing the customer experience through timely service and inspired presentation.

With nearly four decades of success, countless loyal customers, and a strong reputation for excellence, Creative Compliments™ remains a Saskatchewan success story – proof that when creativity meets commitment, the results speak for themselves.

To explore their award-winning gift collections or place an order, visit www.creativecompliments.com or CLICK HERE.

About Creative Compliments™
Founded in 1988, Creative Compliments™ is Saskatchewan’s premier gift basket and floral provider. Serving all of Saskatchewan and shipping nationwide, the company specializes in creative, high-quality designs delivered with exceptional service. With nearly 40 years of experience and numerous accolades, Creative Compliments™ continues to set the standard for professional gifting.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognizing and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com.

Contact Information
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

Y Combinator-backed company raises $6.7M to build breakthrough AI foundation model and releases whitepaper detailing innovative approach to AI behavior modeling

SAN FRANCISCO, CA / ACCESS Newswire / October 16, 2025 / ego AI, a pioneer in AI-driven character technology, today announced the launch of character.world, a character engine built on the company’s novel AI foundation model that mixes small language models with reinforcement learning to create human-like character behavior in games. In addition, ego is introducing its Character Context Protocol (CCP), an open source framework that enables AI characters to maintain persistent personalities, memories and relationships as they move seamlessly between games, apps, Discord servers, streaming platforms, and other digital environments. Together, these two solutions are setting a new standard for believable, persistent AI characters in game play.

“Games and digital worlds have always struggled with flat, scripted non-player characters (NPCs) that feel mechanical and forgettable. ego AI is tackling that head-on with characters who act, react and remember like real players,” said Vishnu Hari, CEO and founder of ego. “Our mission is to move beyond chat windows and give people living, persistent characters who can make games richer, worlds more alive and interactions more meaningful.”

To accelerate development, ego has raised $6.7 million in early seed funding from top institutional investors including Patron, Y Combinator, Accel, Boost VC, and prominent angels such as Balaji Srinivasan (former Coinbase CTO), Logan Kilpatrick (DeepMind), Arjun Sethi (Tribe Capital), Immad Akhund (Mercury), Siqi Chen (Runway), and technical staff from OpenAI, Google Gemini, and Anthropic. The funding is being used to train ego’s foundation model and scale its research and engineering teams.

“What excites me about Ego is their approach to one of gaming’s biggest challenges: creating characters that truly feel alive,” said Adam Draper, founder and partner at Boost VC. “Their foundation model is a breakthrough in AI character behavior. We’re entering a new era where AI characters will carry personality, memory, and emotion-indistinguishable from human players-and Ego is positioned to lead it. And Vish is the most resilient founder in the space.”

ego also released Behavior is All You Need, a comprehensive technical whitepaper that details the company’s approach to creating believable AI characters through four key components: personality, needs, emotion and memory. Unlike traditional chatbots designed for helpfulness, ego’s characters exhibit autonomous behavior, emotional reactivity and the ability to form lasting relationships with players.

ego aims to democratize character development and enable broad industry adoption by releasing CCP as an open-source standard. The protocol defines lightweight interfaces for perception, action and memory that allow developers to integrate persistent characters into existing games and applications with minimal setup. Early implementations of CCP are supporting characters in Unity, Unreal Engine, Roblox and various Discord applications, with plans to expand to additional platforms based on developer interest.

The company has already seen significant market traction, with its Roblox experience attracting over one million users in its first month, and its Discord AI-character game rolling out in partnership with MEE6, one of the platform’s most popular bots.

“Discord communities thrive on engagement and social interaction, but maintaining that energy 24/7 has always been challenging,” said Brian Cho, partner at Patron. “ego’s persistent AI characters bring communities to life even when human members aren’t online. These characters remember conversations, develop relationships with community members and contribute meaningfully to ongoing discussions. It’s transforming how we think about community management and engagement.”

To support the computational demands of training and serving human-like AI characters, ego has partnered with the Singapore government through AI Singapore, along with collaborations with the National University of Singapore and Nanyang Technological University.

“Singapore is committed to advancing AI that delivers meaningful impact across industries,” said Dr. Leslie Teo, Senior Director of AI Products at AI Singapore. “ego’s character engine for human-like behavior marks a pioneering step in social and interactive AI. We look forward to our research collaboration with ego, including providing infrastructure support for training the behaviour foundation model, to accelerate innovation and create opportunities for both our local talent and the global AI and gaming ecosystem.”

Developers can access the CCP specification immediately, with SDK access available through a developer waitlist. The company is also launching “Accomplice,” an AI-powered social deduction game playable on Discord with a Steam release planned.

About ego AI

Founded in 2023, ego AI is building the next generation of AI-powered characters: persistent, believable, and cross-platform. With a team of engineers from Meta AI, Riot and Square and researchers from MIT, CMU, UPenn and the University of Toronto, ego’s vision is to power the future of games, social platforms, and digital experiences with human-like characters. Backed by Y Combinator, leading investors and supported by partnerships with the Singapore Government, ego is headquartered in San Francisco with additional research operations in Singapore and Tokyo. For more information, visit www.egoai.com.

ego Media Contact:
ego@songuepr.com

SOURCE: ego AI

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 financial results, and provide a corporate update.

A live webcast of the call will be available under “Events and Presentations” in the Investors section of the Moderna website.

• Webcast: https://investors.modernatx.com

The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Media Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

SASKATOON, SK / ACCESS Newswire / October 16, 2025 / Greatway Financial Inc. has been recognised with the 2025 Consumer Choice Award in the Life Insurance category for Saskatoon. Family-founded and committed to protecting what matters most for Canadians, the company equips insurance agents with the tools and training needed to guide clients through confident financial decisions.

Founded with a mission to make life insurance and protection planning more accessible and approachable, with a mission to make financial planning more accessible, approachable, Greatway supports its national network of agents with education and resources so families in Saskatoon and across Canada can receive clear, trustworthy guidance tailored to their needs and goals.

“At Greatway Financial, we believe preparing for the future should never feel overwhelming,” says the Greatway Financial team. “Being recognised with the Consumer Choice Award in Saskatoon reflects the trust our clients and partners place in us to help them secure what matters most – whether that’s family, freedom, or future.”

Empowering Agents, Supporting Families

As a Managing General Agency (MGA), Greatway Financial provides insurance agents with professional development, tools, and ongoing support so they can serve families effectively. This helps ensure that Canadians benefit from knowledgeable agents who can simplify important decisions about life insurance and financial protection.

The company’s collaborative approach not only strengthens the success of agents but also builds confidence for families at every stage of life, from young households beginning to plan ahead to retirees focused on protecting their legacy.

Recognition as a 2025 Consumer Choice Award recipient is an important milestone for Greatway Financial. It underscores the company’s dedication to empowering both agents and clients, and highlights its role as a trusted resource in Saskatoon’s life insurance and protection planning community.

A Commitment to Growth and Community

Looking ahead, Greatway Financial remains dedicated to supporting more families across Canada with straightforward, compassionate guidance. By continuing to expand its training programs, strengthen partnerships, and invest in its community, the company is committed to strengthening communities by ensuring licensed agents can provide accessible life insurance and protection to Canadian families.

To learn more about Greatway Financial Inc. or to connect with an agent visit www.greatwayfinancial.com.

About Greatway Financial Inc.
Greatway Financial Inc. is a family-founded Managing General Agency (MGA) dedicated to helping Canadians protect what matters most. By equipping insurance agents with the training and tools they need to succeed, Greatway ensures clients receive clear, confident guidance in life insurance and financial planning. Recognised as a 2025 Consumer Choice Award recipient, Greatway continues to strengthen its impact in Saskatoon and beyond. Learn more at www.greatwayfinancial.com.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognising and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

VANCOUVER, BC / ACCESS Newswire / October 16, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to announce Québec-based BBA Inc. (“BBA”) has been engaged to complete the Lac Jeannine Iron Tailings Project (“Lac Jeannine” or the “Project”) bankable Feasibility Study (the “FS”) to engineer and design its Iron Tailings reclamation Project in Québec, Canada.

Julian Treger, CoTec CEO commented: “Lac Jeannine exemplifies CoTec’s strategy to deploy innovative, environmentally responsible technologies which transform legacy waste sites into valuable resources. The Project has the potential to deliver strong economic returns while simultaneously addressing historical environmental liabilities. Furthermore, the inclusion of adjacent tailings in the Project has the potential to almost double the life of mine with limited additional capex, unlocking substantial upside potential.

We are very excited to be working with BBA to complete the Feasibility Study and to position Lac Jeannine as a model for sustainable tailings redevelopment in Québec. During the Feasibility Study, discussions with strategic partners will be accelerated so the Project has the full support of all stakeholders, including the Government of Québec, First Nations and other interested parties. The results from the 2025 drilling and bulk sample, which are expected in Q1 2026, could also allow CoTec to increase its current resource estimate for Lac Jeannine.”

Lac Jeannine represents CoTec’s first stand-alone tailings reprocessing investment complementing the Company’s strategy to apply advanced technologies to unlock value from underutilized resource assets. The study will build on the positive results of the 2024 Preliminary Economic Assessment (“PEA”) announced on June 27, 2024ⁱ, which was based on only part of the total tailings and outlined a pre-tax NPV of US$93.6 million and an IRR of 38%, based on an initial capital investment of US$64.6 million. The Feasibility Study will include the application of the Salter Cyclone Multi-Gravity Separators (“MGS”) technology for the recovery of additional iron ore from the Project.

The Feasibility Study is expected to be completed through a staged approach by H2 2026. Lac Jeannine has the potential to produce high grade, critical mineral, iron ore concentrate at competitive cost structures which can deliver high purity iron concentrates for the green steel industry. The Lac Jeannine Project offers great potential for the resource industry to recover the economic benefit of large Fe tailing sites.

In September 2025, CoTec completed an infill and extension drilling campaign with the goal of upgrading to Indicated the existing Inferred Mineral Resource of 73 million tonnes at 6.7% total Fe, for 4.9 Mt of contained total Fe, and extending the Project to include a large part of the adjacent tailings not included in the PEA (“Adjacent Tailings”). The inclusion of the Adjacent Tailings has the potential to almost double the life of mine with limited additional capex, unlocking substantial upside potential. The Feasibility Study metallurgy testing will target the production of direct-reduction (“DR”) grade concentrate by the Project.

About Lac Jeannine

The Lac Jeannine Property comprises 31 mineral claims (exclusive exploration rights) covering 1,649 hectares in Québec’s Côte-Nord Region, approximately eight kilometres southeast of Gagnon and 290 kilometres north of Baie-Comeau. The Project encompasses the historic Lac Jeannine open-pit iron mine, which produced approximately 260 million long tons of ore averaging 33% Fe between 1961 and 1976.

The site includes a large Tailings Storage Facility (TSF) where concentrator tailings were deposited prior to mine closure and reclamation in 1984. CoTec’s focus is on reprocessing these tailings for residual iron recovery while rehabilitating the TSF.

The Independent Qualified Person as defined by NI 43-101 for the Lac Jeannine Mineral Resource, Mr. Christian Beaulieu, P.Geo., is a member of l’Ordre des géologues du Québec (#1072). The Qualified Person has reviewed and approved the scientific and technical content of this announcement relating to the Lac Jeannine Mineral Resource

About CoTec Holdings Corp.

CoTec Holdings Corp. (TSX-V:CTH)(OTCQB:CTHCF) is redefining the future of resource extraction and recycling. Focused on rare earth magnets and strategic materials, CoTec integrates breakthrough technologies with strategic assets to unlock secure, sustainable, and low-cost supply chains.

CoTec’s mission is clear: accelerate the energy transition while strengthening strategic critical mineral supply chains for the countries we operate in. By investing in and deploying disruptive technologies, the Company delivers capital-efficient, scalable solutions that transform marginal assets, tailings, waste streams, and recycled products into high-value critical minerals.

From its HyProMag USA magnet recycling joint venture in Texas, to iron tailings reprocessing in Québec, to next-generation copper and iron solutions backed by global majors, CoTec is building a diversified portfolio with long-term growth, rapid cash flow potential, and high barriers to entry. The result is a game-changing platform at the intersection of technology, sustainability, and strategic materials.

For more information, please visit www.cotec.ca.

For further information, please contact:

Braam Jonker – (604) 992-5600

Forward-Looking Information Cautionary Statement

Statements in this press release regarding the Company and its investments which are not historical facts are “forward-looking statements” which involve risks and uncertainties, including statements relating to the timing, scope, and completion of the Feasibility Study, the potential future value of the Project, the maiden resource estimate, the bulk sample extraction, the option exercise, and the Project, as well as management’s expectations with respect to the Lac Jeannine investment and other current and potential future investments, and the benefits to the Company which may be implied from such statements.

Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements due to known and unknown risks and uncertainties affecting the Company, including but not limited to: resource and reserve risks; environmental risks and costs; permitting and regulatory risks; labor costs and shortages; uncertain supply and price fluctuations in materials; increases in energy costs; labor disputes and work stoppages; equipment leasing and availability; heavy equipment demand and availability; contractor and subcontractor performance; worksite safety issues; project delays and cost overruns; extreme weather events; and social, transport, or geopolitical disruptions.

For further details regarding risks and uncertainties facing the Company, please refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, a copy of which may be found under the Company’s profile on SEDAR+ (www.sedarplus.ca). The Company assumes no obligation to update forward-looking statements in this press release except as required by law. Readers should not place undue reliance on the forward-looking statements and information contained in this news release and are encouraged to read the Company’s continuous disclosure documents available on SEDAR+ (www.sedarplus.ca).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

ⁱ For further details, please refer to the technical report entitled “Mineral Resource Estimate, Preliminary Economic Assessment and NI 43-101 technical report for CoTec’s Lac Jeannine Fe Tailings Project, Québec, Canada” dated August 5, 2024 and having an effective date of March 19, 2024 prepared by Addison Mining Services Ltd., JPL GeoServices Inc., Soutex Inc., Amerston Consulting Ltd. and Axe Valley Mining Consultants Ltd. A copy of the technical report is available under CoTec’s profile on SEDAR+ (www.sedarplus.com) and the Company’s website

SOURCE: CoTec Holdings Corp.

View the original press release on ACCESS Newswire

• Enterprise platform, queried through natural language, to help pharma, biotech, and investors make better decisions.

• High-quality biological patient data, enriched and integrated for use by AI agents.

PARIS, FRANCE / ACCESS Newswire / October 16, 2025 / Owkin today announces the launch of K Pro, its co-pilot bringing advanced agentic AI to biomedical research and drug development. K Pro helps pharmaceutical companies and biotechs make smarter decisions across the discovery and development pipeline, increase clinical success rates, and deliver decision-grade, data-driven biological insights fast enough to change program trajectories.

Built on a decade of Owkin’s AI innovation and in close collaboration with leading academic and industry partners, K Pro is a scientist-first co-pilot, accessible to both researchers and executives. Through natural language interaction, users can ask complex biological questions and receive actionable, clinically relevant answers, unifying fragmented workflows into an insight-driven research experience.

At its core, K Pro integrates Owkin Zero, a fine-tuned biological LLM that performs biological reasoning with higher performance than other leading LLMs (read the full paper). Leveraging high-quality, multimodal biomedical datasets, K Pro gives researchers access to one of the deepest, curated, AI-ready multimodal oncology datasets available (including MOSAIC). Biopharma and academic clients can securely upload their proprietary datasets to leverage K Pro’s advanced AI reasoning and data analysis.

Thomas Clozel, MD, Owkin Co-founder and CEO, said: “K Pro brings us closer to intelligence that evolves with the complexity of biology. By combining advanced biological reasoning with an agentic co-pilot architecture, it represents a key step towards our mission of achieving Biological Artificial Super Intelligence (BASI), AI capable of modelling and engineering biology beyond what humans are capable of to deliver transformative therapies to patients faster.”

K Pro has already accelerated internal drug target identification by 70% (from 12+ months to 3 months); built an IND-ready asset positioning strategy in hours instead of months of traditional analysis; and written a specialist review in one day, which was later published in a peer-reviewed scientific journal.

K Pro builds upon Owkin’s proven approach to agentic AI biomedical discovery, validated through collaborations with leading pharmaceutical companies including AstraZeneca, Bristol Myers Squibb and Sanofi.

Ben Mellows, managing director at the biotech company Micregen, used Owkin K to formulate his investor pitch and shared his experience: “We wanted to get our product pitch across to investors. That process could take weeks to work through with all of our experts, but Owkin K really helped. It assimilated all the information we provided evidencing how our regenerative stem cell-derived platform and products could have a major impact on healthcare and delivered a clear story tailored to investors from different backgrounds. The literature set is huge. I would say the task would have been nearly impossible to achieve at the scale that Owkin K handled in just a few work sessions.”

Owkin’s AI has already delivered results for pharmaceutical clients, including: preventing Phase 2 clinical trial futility by identifying high-risk combination therapy populations; discovering new multimodal disease endotypes; reducing trial duration by three years (35%) by identifying the right patient segment to inform enrolment and identifying novel oncology targets.

About Owkin:
Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI co-pilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.

About the State of Agentic AI in Biopharma Report:
To ensure K Pro addresses the real-world challenges facing pharma, Owkin partnered with STAT Brand Studio to produce the State of the Nation report, surveying over 200 pharma executives (full report here). Nearly half of respondents identified overcoming data challenges as the area where agentic AI could deliver the greatest value. Early discovery, clinical trial optimisation, and translational research were also highlighted as top priorities, underscoring the immediate need for agentic AI solutions that translate complex biomedical data into actionable insights.

SOURCE: Owkin

Related Images

View the original press release on ACCESS Newswire